{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03406780",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CAP-1002-DMD-02"
      },
      "Organization": {
        "OrgFullName": "Capricor Inc.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy",
      "OfficialTitle": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy",
      "Acronym": "HOPE-2"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 4, 2018",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 10, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 10, 2020",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "January 15, 2018",
      "StudyFirstSubmitQCDate": "January 19, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 23, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "June 3, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 5, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Capricor Inc.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.",
      "DetailedDescription": "Approximately 84 eligible study participants will be randomized to either CAP-1002 or placebo in a 1:1 ratio.\nThe trial will include visits at Screening, Baseline/Day 1, Week 4, and Months 3, 6, 9, and 12 with IV infusions of CAP-1002 or placebo on Day 1 and Months 3, 6, and 9.\nSafety evaluations will include adverse events, concomitant medications, physical exam, vital signs, 12-lead ECG, and clinical laboratory testing.\nEfficacy will be evaluated in the Performance of the Upper Limb, pulmonary function testing, North Star Ambulatory Assessment (ambulatory subjects only), strength testing, cardiac MRI, and quality of life.\nIf trial data suggests an appropriate risk/benefit profile of CAP-1002, Capricor, upon the recommendation of the Data Safety Monitoring Board (DSMB), will introduce an open-label extension study to offer CAP-1002 to study participants who were randomized to placebo and completed all trial visits during the 12-month period."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Muscular Dystrophies",
          "Muscular Dystrophy, Duchenne",
          "Muscular Disorders, Atrophic",
          "Muscular Diseases",
          "Neuromuscular Diseases",
          "Nervous System Diseases",
          "Genetic Diseases, X-Linked",
          "Genetic Diseases, Inborn"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Duchenne Muscular Dystrophy",
          "Cell Therapy",
          "Performance of the Upper Limb",
          "Pulmonary Function",
          "Ambulatory",
          "Non-Ambulatory",
          "Glucocorticoids"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "18",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "CAP-1002",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: CAP-1002"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "CAP-1002",
            "InterventionDescription": "The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "CAP-1002"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Cardiosphere-Derived Cells",
                "CDCs"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Placebo",
            "InterventionDescription": "Placebo",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in the mid-level (elbow) dimension of the Performance of the Upper Limb (PUL)",
            "PrimaryOutcomeDescription": "The PUL includes functional tasks that relate to activities of daily living that are very important for quality of life. The PUL has been validated for the assessment of upper limb motor function in individuals with DMD.",
            "PrimaryOutcomeTimeFrame": "Month 12"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in the mid-level (elbow) dimension of the PUL",
            "SecondaryOutcomeDescription": "The PUL includes functional tasks that relate to activities of daily living that are very important for quality of life. The PUL has been validated for the assessment of upper limb motor function in individuals with DMD.",
            "SecondaryOutcomeTimeFrame": "Months 3, 6, and 9"
          },
          {
            "SecondaryOutcomeMeasure": "Change in regional systolic left ventricular wall thickening as assessed by cardiac MRI",
            "SecondaryOutcomeDescription": "Systolic thickening is thought to be a principal mechanism of cardiac output generation in people with DMD.",
            "SecondaryOutcomeTimeFrame": "Months 6 and 12"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nGenetically confirmed DMD\nReduced upper arm strength as measured by the Performance of Upper Limb\nReduced ability to walk/run (if ambulatory)\nTreatment with systemic glucocorticoids for at least 12 months and at a stable dose at least 6 months prior to study participation, except for weight-based or toxicity-related adjustments\nCurrent and up-to-date immunizations\n\nExclusion Criteria:\n\nLeft ventricular ejection fraction < 35%\nBMI > 45\nAmbulant if â‰¥ 18 years of age\nExon 44 skip-amenable mutation(s) in the DMD gene\nDeletion mutation(s) encompassing exons 3-7 of the DMD gene\nPercent-predicted forced vital capacity (FVC) < 35%\nChronic respiratory disease not related to DMD (for example, asthma, bronchitis, and tuberculosis)\nHistory of diabetes requiring treatment with metformin or insulin within 3 months prior to randomization\nTreatment with an FDA-approved exon skipping therapy for the treatment of DMD if on a stable dose for less than 24 months prior to randomization\nTreatment with human growth hormone (HGH) within 3 months prior to randomization, unless on a stable dose for at least 24 months prior to randomization\nTreatment with idebenone within 3 months prior to randomization\nTreatment with a cell therapy product within 12 months prior to randomization\nTreatment with an investigational product within 6 months prior to randomization",
      "HealthyVolunteers": "No",
      "Gender": "Male",
      "MinimumAge": "10 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Craig McDonald, MD",
            "OverallOfficialAffiliation": "University of California, Davis",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of California, Davis",
            "LocationCity": "Sacramento",
            "LocationState": "California",
            "LocationZip": "95817",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Children's Hospital Colorado",
            "LocationCity": "Aurora",
            "LocationState": "Colorado",
            "LocationZip": "80045",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Nemours Children's Hospital",
            "LocationCity": "Orlando",
            "LocationState": "Florida",
            "LocationZip": "32827",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Washington University",
            "LocationCity": "Saint Louis",
            "LocationState": "Missouri",
            "LocationZip": "63110",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Cincinnati Children's Hospital Medical Center",
            "LocationCity": "Cincinnati",
            "LocationState": "Ohio",
            "LocationZip": "45229",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Utah",
            "LocationCity": "Salt Lake City",
            "LocationState": "Utah",
            "LocationZip": "84112",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Children's Hospital Wisconsin",
            "LocationCity": "Milwaukee",
            "LocationState": "Wisconsin",
            "LocationZip": "53226",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Company website",
            "SeeAlsoLinkURL": "http://capricor.com"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009136",
            "ConditionMeshTerm": "Muscular Dystrophies"
          },
          {
            "ConditionMeshId": "D000020388",
            "ConditionMeshTerm": "Muscular Dystrophy, Duchenne"
          },
          {
            "ConditionMeshId": "D000009135",
            "ConditionMeshTerm": "Muscular Diseases"
          },
          {
            "ConditionMeshId": "D000020966",
            "ConditionMeshTerm": "Muscular Disorders, Atrophic"
          },
          {
            "ConditionMeshId": "D000009422",
            "ConditionMeshTerm": "Nervous System Diseases"
          },
          {
            "ConditionMeshId": "D000009468",
            "ConditionMeshTerm": "Neuromuscular Diseases"
          },
          {
            "ConditionMeshId": "D000030342",
            "ConditionMeshTerm": "Genetic Diseases, Inborn"
          },
          {
            "ConditionMeshId": "D000040181",
            "ConditionMeshTerm": "Genetic Diseases, X-Linked"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11245",
            "ConditionBrowseLeafName": "Muscular Dystrophies",
            "ConditionBrowseLeafAsFound": "Muscular Dystrophy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11244",
            "ConditionBrowseLeafName": "Muscular Diseases",
            "ConditionBrowseLeafAsFound": "Muscular Diseases",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11563",
            "ConditionBrowseLeafName": "Neuromuscular Diseases",
            "ConditionBrowseLeafAsFound": "Neuromuscular Diseases",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3741",
            "ConditionBrowseLeafName": "Atrophy",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21338",
            "ConditionBrowseLeafName": "Muscular Dystrophy, Duchenne",
            "ConditionBrowseLeafAsFound": "Muscular Dystrophy, Duchenne",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafAsFound": "Genetic Diseases",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21850",
            "ConditionBrowseLeafName": "Muscular Disorders, Atrophic",
            "ConditionBrowseLeafAsFound": "Muscular Disorders, Atrophic",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M24030",
            "ConditionBrowseLeafName": "Genetic Diseases, X-Linked",
            "ConditionBrowseLeafAsFound": "Genetic Diseases, X-Linked",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3963",
            "ConditionBrowseLeafName": "Muscular Dystrophy",
            "ConditionBrowseLeafAsFound": "Muscular Dystrophy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T698",
            "ConditionBrowseLeafName": "Becker Muscular Dystrophy",
            "ConditionBrowseLeafAsFound": "Duchenne",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1945",
            "ConditionBrowseLeafName": "Duchenne Muscular Dystrophy",
            "ConditionBrowseLeafAsFound": "Duchenne Muscular Dystrophy",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M8199",
            "InterventionBrowseLeafName": "Glucocorticoids",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M11052",
            "InterventionBrowseLeafName": "Mitogens",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}